Key Highlights

  • Shareholders approved an amendment to the 2025 Incentive Award Plan, adding 900,000 shares for issuance.
  • At the July 8 meeting, 4,985,176 shares were represented, accounting for roughly 51.75% of the company’s common stock.
  • The meeting resulted in the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as independent auditor.

Seres Therapeutics, Inc. (NASDAQ: MCRB) held its 2026 Annual Meeting of Stockholders after reconvening from a June 9 adjournment caused by insufficient quorum. The gathering on July 8, 2026, served as a platform for several governance actions that could shape the biotech firm’s strategic direction.

Meeting Reconvened

The Annual Meeting was reassembled after the earlier quorum shortfall, allowing shareholders to address pending proposals. The reconvened session enabled the company to move forward on essential corporate matters without further delay.

Incentive Plan Expansion

Shareholders voted to amend and restate the 2025 Incentive Award Plan, increasing the pool of shares eligible for issuance by 900,000. This adjustment is intended to strengthen retention and recruitment of key talent within Seres Therapeutics. This level of participation met the thresholds required for the approval of the agenda items.

Board Elections

The ballot included the election of three Class II directors who will serve until the 2029 Annual Meeting. All nominated candidates secured the necessary votes, ensuring continuity on the board’s oversight responsibilities. The firm’s continued engagement underscores the company’s commitment to strong financial reporting standards.

Advisory Compensation Vote

An advisory, non‑binding vote on the compensation of named executive officers was approved by the shareholders. While the outcome does not bind management, it provides insight into investor sentiment regarding executive pay structures.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.